Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 6/20 | 0.42 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.41 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | YTHDC1 | Q96MU7 | 2/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | AHCY | P23526 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.34 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6368852 | 0.81 | CDK1 (0.44) | CDK1CCNB1CCNE1CDK2PDE4A | |
| SCHEMBL27392700 | 0.79 | CDK1 (0.43) | CDK1CCNB1CCNE1CDK2PDE4A | |
| 9-Methylguanine SCHEMBL2787045 | 0.78 | CDK1 (0.59) | CDK1CCNB1CCNE1CDK2PDE4A | |
| SCHEMBL16750272 | 0.78 | AHCY (0.38) | AHCY | |
| SCHEMBL20656164 | 0.77 | CDK2 (0.49) | CDK1CCNB1CCNE1CDK2ADORA1 | |
| SCHEMBL25665533 | 0.75 | PDE4A (0.49) | CDK1CCNB1CCNE1CDK2PDE4A | |
| SCHEMBL21128173 | 0.75 | CDK1 (0.40) | CDK1CCNB1CCNE1CDK2PDE4A | |
| SCHEMBL13828347 | 0.75 | CDK1 (0.43) | CDK1CCNB1CCNE1CDK2PDE4A | |
| SCHEMBL19978921 | 0.75 | CDK1 (0.40) | CDK1CCNB1CCNE1CDK2PDE4A | |
| SCHEMBL13828319 | 0.75 | YTHDC1 (0.66) | CDK2PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210052721-A1 | HEPATITIS C VIRUS PEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2021-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210052721-A1 | HEPATITIS C VIRUS PEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF | HLA-DRB1, CD4, HLA-C | CDK1 2299/4885CCNB1 1346/4885CCNE1 394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.